The Current Ratio as of September 2024 (TTM) for Gracell Biotechnologies Inc. (GRCL) is 7.73

According to Gracell Biotechnologies Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.73. This represents a change of 13.67% compared to the average of 6.80 of the last 4 quarters.

Gracell Biotechnologies Inc. (GRCL) Historical Current Ratio (quarterly & annually)

How has GRCL Current Ratio performed in the past?

The mean historical Current Ratio of Gracell Biotechnologies Inc. over the last ten years is 12.72. The current 7.73 Current Ratio has changed 5.98% with respect to the historical average. Over the past ten years (40 quarters), GRCL's Current Ratio was at its highest in in the December 2019 quarter at 18.74. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Gracell Biotechnologies Inc. (GRCL) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Gracell Biotechnologies Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Gracell Biotechnologies Inc. (GRCL) Average Current Ratio

How has GRCL Current Ratio performed in the past?

The current Current Ratio of Gracell Biotechnologies Inc. (GRCL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Gracell Biotechnologies Inc. (GRCL) Current Ratio vs. Peers

How is GRCL’s Current Ratio compared to its peers?

Gracell Biotechnologies Inc.’s Current Ratio is less than Theseus Pharmaceuticals, Inc. (29.93), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Erasca, Inc. (16.79), less than NextCure, Inc. (8.35), greater than CytomX Therapeutics, Inc. (1.00), less than Neoleukin Therapeutics, Inc. (15.33), greater than Spero Therapeutics, Inc. (2.68), greater than Assembly Biosciences, Inc. (2.74), less than Terns Pharmaceuticals, Inc. (21.02), greater than Amylyx Pharmaceuticals, Inc. (4.66), less than Acumen Pharmaceuticals, Inc. (17.37), less than Inozyme Pharma, Inc. (9.84), greater than X4 Pharmaceuticals, Inc. (6.07), greater than Bolt Biotherapeutics, Inc. (4.28), greater than Coherus BioSciences, Inc. (1.21), less than Icosavax, Inc. (18.06), greater than Day One Biopharmaceuticals, Inc. (4.09), greater than Decibel Therapeutics, Inc. (3.03), greater than Blueprint Medicines Corporation (3.71),

Build a custom stock screener for Gracell Biotechnologies Inc. (GRCL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gracell Biotechnologies Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Gracell Biotechnologies Inc. (GRCL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Gracell Biotechnologies Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.